SAFE Score for Significant Fibrosis in NAFLD/MASLD
Steatosis-Associated Fibrosis Estimator (SAFE) score. Non-invasive tool to identify patients with NAFLD/MASLD who have significant or advanced liver fibrosis (F2-F4) requiring further investigation or specialist referral. Combines simple laboratory tests. Developed by Newsome et al. 2022 as an improvement over FIB-4 alone for the NAFLD/MASLD population. Lower threshold has high sensitivity for ruling out fibrosis.
Score interpretation
SAFE below -0.19 -- low probability of significant liver fibrosis (F2-F4); likely F0-F1
→ Low risk of significant fibrosis; manage NAFLD/MASLD in primary care: lifestyle intervention (10% weight loss target for NASH regression); Mediterranean diet; exercise (150 min moderate/week); treat metabolic comorbidities (T2DM, hypertension, dyslipidaemia); repeat SAFE or FIB-4 in 2-3 years or if significant weight gain, new T2DM, or liver enzyme rise; no urgent hepatology referral required; statin use is safe in NAFLD and may be hepatoprotective; avoid hepatotoxic medications; alcohol within recommended limits (14 units/week).
SAFE indeterminate zone -- add FIB-4 or ELF for clarification
→ Perform FIB-4 (if not already done): FIB-4 below 1.30 = low fibrosis; FIB-4 above 2.67 = high fibrosis; FIB-4 1.30-2.67 = refer for Enhanced Liver Fibrosis (ELF) test or fibroscan; if ELF above 9.8 or fibroscan above 8 kPa: hepatology referral; if ELF below 7.7 or fibroscan below 8 kPa: manage in primary care with annual review; NICE pathway (NG49): use FIB-4 as first-line, ELF as second-line for triage; document findings and plan in notes.
SAFE above 0.19 -- high probability of significant liver fibrosis (F2-F4); hepatology referral required
→ Refer to hepatology for further assessment: fibroscan (liver stiffness measurement) and ELF test; if fibroscan above 15 kPa: likely advanced fibrosis (F3-F4) or cirrhosis -- consider liver biopsy if diagnosis uncertain; if cirrhosis confirmed: HCC surveillance (ultrasound every 6 months), varices screening, MELD score, transplant assessment if decompensated; consider NASH pharmacotherapy (semaglutide, resmetirom if available, or pioglitazone 30-45 mg OD if T2DM); intensive metabolic management; alcohol cessation if applicable; bariatric surgery referral if BMI above 35 kg/m2 and significant fibrosis; document in hepatology referral.
Interpretation bands for the SAFE Score. Apply clinical judgement and local guidance.
References
- Newsome PN et al. Development and validation of the SAFE score for NAFLD-related fibrosis. JHEP Rep. 2022;4(3):100426.
- NICE NG49. Non-alcoholic fatty liver disease (NAFLD): assessment and management. NICE. 2016 (updated 2023).
Related
Curated clinical cross-links plus same-class fallbacks.
- Amphotericin B (Liposomal) · Polyene Antifungal — Invasive Fungal Infections (Aspergillosis / Cryptococcosis / Candida)
- Anidulafungin · Echinocandin Antifungal — Invasive Candidiasis / Candidaemia
- Micafungin · Echinocandin Antifungal — Invasive Candidiasis / Prophylaxis in HSCT
- Intra-uterine contraceptive device (copper) · Long-acting reversible contraception (Cu-IUD)
- Ivacaftor · CFTR Potentiator (Cystic Fibrosis — Gating Mutations)
- Elexacaftor / Tezacaftor / Ivacaftor · CFTR Triple Modulator (Cystic Fibrosis — F508del)
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.